The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a pivotal
role in mediating cell size and mass, proliferation, and survival. mTOR has also emerged as …

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a
fundamental role in regulating cellular homeostasis and metabolism. In a two-part review …

The immunosuppressive drug rapamycin has helped to identify a large signaling network
around the target of rapamycin (TOR) protein that integrates information on nutrient …

Mammalian target of rapamycin (mTOR) is the core component of two complexes, mTORC1
and mTORC2. mTORC1 is inhibited by rapamycin and analogues. mTORC2 is impeded …

Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a
targeted mechanism in the treatment of renal cell carcinoma (RCC). Temsirolimus, an mTOR …

Inhibition of the mammalian target of rapamycin (mTOR) shows beneficial effects in animal
models of polycystic kidney disease (PKD); however, two clinical trials in patients with …

Aberrant activation of the mammalian target of rapamycin (mTOR) pathway occurs in
polycystic kidney disease (PKD). mTOR inhibitors, such as rapamycin, are highly effective in …

Inhibitors of the mammalian target of rapamycin (MTOR) belong to a family of drugs with
potent immunosuppressive, antiangiogenic, and antiproliferative properties. De novo or …

Use of the mammalian target of rapamycin (mTOR) inhibitor rapamycin in organ
transplantation has evolved through different phases over the past two decades. After its …

The mammalian target of rapamycin (mTOR) was recently identified in two structurally
distinct multiprotein complexes: mTORC1 and mTORC2. Previously, we found that …